Over the past decade, experts in the field of nanotechnology and materials science have been trying to devise architectures ...
Discover the top biotech deals of September 2025, as four billion-dollar acquisitions took place and several licensing deals ...
During the week, 17 Indian startups raised a total of $206.89 million, comprising 6 growth-stage and 10 early-stage deals, ...
Prurigo Nodularis market to exhibit growth at a CAGR of 23.2% (2020-2034), driven by strong uptake of DUPIXENT, recent approval of NEMLUVIO, promising JAK and OX40 inhibitors in the Pipeline, along ...
With the business potentially at an important milestone, we thought we'd take a closer look at Vertex, Inc.'s (NASDAQ:VERX) future prospects. Vertex, Inc., together with its subsidiaries, provides ...
Vertex Pharmaceuticals remains a buy, anchored by its dominant cystic fibrosis (CF) franchise and optionality in JOURNAVX. VRTX's near-term growth hinges on JOURNAVX's commercial ramp and pivotal ...
NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...
The Punjab Central Business District Development Authority (PCBDDA), commonly known as Central Business District Punjab (CBD Punjab), has taken another bold step in reshaping skyline of the Punjab's ...
- Food and Drug Administration granted Breakthrough Therapy Designation for povetacicept in IgA nephropathy; on track to file for accelerated approval in the U.S. in H1 2026 if 36-week interim ...
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...
Fintel reports that on September 25, 2025, Leerink Partners upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Market Perform to Outperform. Analyst Price Forecast Suggests 30.19% ...
If you have been eyeing Vertex Pharmaceuticals and wondering whether it is the right time to buy, sell, or simply hold tight, you are far from alone. Vertex has been on a journey, sometimes up, ...